By Dr Jennifer Rebecca Snaith

Journal articles

Frampton R; Snaith JR; Hocking S; Holmes-Walker J; Olsen N; Greenfield JR, 2024, 'Reducing cardiometabolic risk with semaglutide in type 1 diabetes (RESET1): Study protocol of a phase 2 double-blinded randomised placebo-controlled trial', Diabetic Medicine, 41, http://dx.doi.org/10.1111/dme.15377

JANUSZEWSKI AS; SNAITH JR; KOWALSKI GM; BRUCE C; HOLMES-WALKER J; JENKINS A; GREENFIELD J, 2024, '1607-P: Estimation of Muscle and Hepatic Insulin Sensitivity in Type 1 Diabetes Adults Using Clinical and Research Biomarkers', Diabetes, 73, http://dx.doi.org/10.2337/db24-1607-p

SNAITH JR; OLSEN ND; KOWALSKI GM; BRUCE C; EVANS JL; JANUSZEWSKI AS; JENKINS A; BREIT SN; HOLMES-WALKER J; GREENFIELD J, 2024, '865-P: Metformin Reduces Insulin Dose and Visceral Fat Accumulation, and Increases GDF15 without Reducing Insulin Resistance in Adults with Type 1 Diabetes—A 26-Week, Randomized, Double-Blind Placebo-Controlled Trial (INTIMET)', Diabetes, 73, http://dx.doi.org/10.2337/db24-865-p

Forner P; Snaith J; Greenfield JR, 2024, 'Prescribing patterns of adjunctive therapy for the treatment of type 1 diabetes mellitus among Australian endocrinologists', Internal Medicine Journal, 54, pp. 779 - 785, http://dx.doi.org/10.1111/imj.16312

Lamaro BD; Greenfield JR; Snaith JR, 2024, 'Can Unmet Needs Be Addressed by Adjunctive Therapies? Findings from a Patient Perspectives Survey in Adults with Type 1 Diabetes', Journal of Patient Experience, 11, http://dx.doi.org/10.1177/23743735241257811

Snaith JR; Olsen N; Kowalski G; Bruce C; Holmes-Walker J; Greenfield JR, 2023, 'OR18-03 Peripheral But Not Hepatic Insulin Resistance Associates With Adverse Vascular And Metabolic Health In Type 1 Diabetes: A Possible Target For Adjunctive Therapy', Journal of the Endocrine Society, 7, http://dx.doi.org/10.1210/jendso/bvad114.895

Snaith JR; Greenfield JR; Malozowski S; Weghuber D; Kelly AS; Arslanian S, 2023, 'Once-Weekly Semaglutide in Adolescents with Obesity', New England Journal of Medicine, 388, pp. 1145, http://dx.doi.org/10.1056/NEJMc2300510

Snaith JR; Greenfield JR, 2022, 'Sodium–glucose cotransporter 2 inhibitors in type 1 diabetes: a missed opportunity for cardiovascular protection?', Medical Journal of Australia, 217, pp. 126 - 128, http://dx.doi.org/10.5694/mja2.51637

Snaith JR; Danta M; Greenfield JR, 2021, 'Metabolic dysfunction-associated fatty liver disease and insulin resistance in type 1 diabetes', The Lancet Gastroenterology and Hepatology, 6, pp. 985 - 986, http://dx.doi.org/10.1016/S2468-1253(21)00343-5

Snaith JR; Samocha-Bonet D; Evans J; Liu Z; Kowalski G; Bruce C; Holmes-Walker DJ; Greenfield JR, 2021, 'Insulin resistance in type 1 diabetes managed with metformin (INTIMET): Study protocol of a double-blind placebo-controlled, randomised trial', Diabetic Medicine, 38, http://dx.doi.org/10.1111/dme.14564

Snaith JR; Holmes-Walker DJ, 2021, 'Technologies in the management of type 1 diabetes', Medical Journal of Australia, 214, pp. 202 - 205.e1, http://dx.doi.org/10.5694/mja2.50946

Snaith JR; McLeod D; Richardson A; Chipps D, 2020, 'Multifocal insulinoma secondary to insulinomatosis: persistent hypoglycaemia despite total pancreatectomy', ENDOCRINOLOGY DIABETES AND METABOLISM CASE REPORTS, http://dx.doi.org/10.1530/EDM-20-0091

Htet TD; Godneva A; Liu Z; Chalmers E; Kolobkov D; Snaith JR; Richens R; Toth K; Danta M; Hng TM; Elinav E; Segal E; Greenfield JR; Samocha-Bonet D, 2020, 'Rationale and design of a randomised controlled trial testing the effect of personalised diet in individuals with pre-diabetes or type 2 diabetes mellitus treated with metformin', BMJ Open, 10, pp. e037859, http://dx.doi.org/10.1136/bmjopen-2020-037859

Snaith JR; Holmes-Walker DJ; Greenfield JR, 2020, 'Letter to the editor: ⇜risk factors for cardiovascular disease (CVD) in adults with type 1 diabetes: findings from prospective real-life T1D exchange registry”', Journal of Clinical Endocrinology and Metabolism, 105, pp. 1 - 2, http://dx.doi.org/10.1210/clinem/dgaa383

Snaith JR; Greenfield JR, 2020, 'COVID-19: it's changed us', Internal Medicine Journal, 50, pp. 1162 - 1163, http://dx.doi.org/10.1111/imj.14968

Snaith JR; Samocha-Bonet D; Holmes-Walker DJ; Greenfield JR, 2020, 'MON-LB113 Insulin Resistance in Type 1 Diabetes Managed With Metformin (INTIMET): Rationale and Study Design of a Randomised Placebo-Controlled Trial', Journal of the Endocrine Society, 4, http://dx.doi.org/10.1210/jendso/bvaa046.2038

Snaith JR; Gao B; Chipps D; Girgis CM, 2020, 'Massive adrenal hyperplasia from paraneoplastic adrenocorticotropic hormone', BMJ Case Reports, 13, http://dx.doi.org/10.1136/bcr-2020-234892

Snaith JR; Holmes-Walker DJ; Greenfield JR, 2020, 'Reducing Type 1 Diabetes Mortality: Role for Adjunctive Therapies?', Trends in Endocrinology and Metabolism, 31, pp. 150 - 164, http://dx.doi.org/10.1016/j.tem.2019.11.007

Kim A; Snaith JR; Mahajan H; Holmes-Walker DJ, 2019, 'Nesidioblastosis following laparoscopic sleeve gastrectomy', Clinical Endocrinology, 91, pp. 906 - 908, http://dx.doi.org/10.1111/cen.14083

Snaith JR; Holmes-Walker DJ; Greenfield JR, 2019, 'Association of insulin dose, cardiometabolic risk factors, and cardiovascular disease in type 1 diabetes during 30 years of follow-up in the DCCT/EDIC study. Diabetes care 2019;42:657-664', Diabetes Care, 42, pp. E135 - E136, http://dx.doi.org/10.2337/dc19-0730

Snaith JR; Holmes-Walker DJ; Girgis CM; Greenfield JR, 2019, 'Excess mortality and cardiovascular disease risk in type 1 diabetes', The Lancet, 393, pp. 984 - 985, http://dx.doi.org/10.1016/S0140-6736(18)33050-2

Chi C; Snaith J; Gunton JE, 2017, 'Diabetes Medications and Cardiovascular Outcomes in Type 2 Diabetes', Heart Lung and Circulation, 26, pp. 1133 - 1141, http://dx.doi.org/10.1016/j.hlc.2017.02.030

Snaith J; Burns K; Kok J; Chen S; Cheung NW, 2016, 'A case of rhino-orbital mucormycosis in diabetes with haematogenous cerebral spread', Medical Mycology Case Reports, 13, pp. 22 - 24, http://dx.doi.org/10.1016/j.mmcr.2016.10.002

Back to profile page